Skip to content
EntityQ7307897· pop 10· linked from 196 articles

Regadenoson

Sign in to save

Also known as Rapiscan®, Lexiscan®, regadenoson anhydrous, CVT-3146, Regadenoson anhydrous

Regadenoson, sold under the brand name Lexiscan among others, is an A2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing. It produces hyperemia quickly and maintains it for a duration that is useful for radionuclide myocardial perfusion imaging. The selective nature of the drug makes it preferable to other stress agents such as adenosine, which are less selective and therefore cause more side-effects.

Research

549 papers

via PubMed

~3 min read

Encyclopedic overview

1 sections
Contents
  • References

{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 413312613 | IUPAC_name = 2-{4-[(methylamino)carbonyl]- 1H-pyrazol-1-yl}adenosine | image = Regadenoson structure.svg | image_class = skin-invert-image | width = 300

| tradename = Lexiscan, Rapiscan | Drugs.com = | DailyMedID = Regadenoson | pregnancy_AU = | pregnancy_category = | routes_of_administration = Intravenous | ATC_prefix = C01 | ATC_suffix = EB21 | ATC_supplemental =

Excerpted from Wikipedia’s “Regadenoson” article, available under the CC BY-SA 4.0 licence.

Available in 9 languages

via Wikidata sitelinks · CC0